BioSpace News Archive

Business

BIO to Outline Key Priorities for Next Pandemic During Senate Hearing

COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.

June 24, 2020
·
3 min read
·
Alex Keown
Drug Development

FDA Approves Phase III Study of Fulcrum’s Losmapimod in COVID-19

Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.

June 24, 2020
·
3 min read
·
Alex Keown
BioSpace Global Roundup, June 25

Biopharma and life sciences companies provide updates on their pipelines and business plans.

June 24, 2020
·
7 min read
·
Alex Keown
vfCRISPR Uses Light to Bring Precision and Speed to Gene Editing

Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.

June 24, 2020
·
3 min read
·
Gail Dutton
Drug Development

New Data Shows 718 Pipeline Drugs Now Associated with COVID-19

New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages.

June 24, 2020
·
3 min read
·
Krystle Vermes
BioCapital

AsclepiX Launches with $35 Million to Study Diseases of the Eye and Cancer

Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.

June 24, 2020
·
3 min read
·
Mark Terry
Business

Fauci, Other Top Healthcare Officials Outline Necessary Strategies to Combat COVID-19

Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.

June 24, 2020
·
3 min read
·
Alex Keown
Business

Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs.

June 24, 2020
·
3 min read
·
Mark Terry
Deals

BioGeneration Ventures Closes BGV IV Fund at €105 Million

BioGeneration Ventures, a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at €105 million.

June 24, 2020
·
4 min read
Business

Diamyd Medical AB (publ) Quarterly Report III 19/20 -September 2019 - May 2020, Fiscal year 2019/2020

Net result: MSEK 23.2 (-26.8), whereof third quarter MSEK -7.2 (-7.9). The increase compared to previous year is a one-off effect due to a payment of corresponding MSEK 48.0 from the previous GAD65 manufacturer as support for transition of the manufacturing process.

June 24, 2020
·
12 min read